At a glance
- Originator SICOR
- Developer PeriCor Therapeutics; SICOR
- Class Anti-ischaemics; Antithrombotics; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Purinergic P1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Angina pectoris; Myocardial ischaemia; Unstable angina pectoris